Core Insights - The announcements highlight significant corporate activities including investments, acquisitions, and sales performance in various companies across different sectors. Company Announcements - Chunzhong Technology clarified that its business does not involve the production of liquid-cooled servers [1] - Fangzheng Technology plans to invest 1.364 billion yuan in the expansion of its artificial intelligence production base in Chongqing [1] - Chongqing Construction Group won a contract for an engineering project valued at approximately 1.839 billion yuan [1] - Guocheng Mining intends to acquire 60% of Guocheng Industry for 3.168 billion yuan [1] - Ruikang Pharmaceutical has completed a share buyback, acquiring 2.31% of its shares [1][2] - Jianghuai Automobile reported October sales of 31,500 units, a year-on-year increase of 5.49% [1][2] - GAC Group's October automobile sales were 170,700 units, reflecting a year-on-year decline of 8.10% [1][2] Shareholding Changes - Jiangsu Cable's controlling shareholder plans to increase its stake by 100 million to 150 million yuan [1] - Yingshi Sheng's actual controller, Tang Qiu, intends to reduce his stake by no more than 1.86% [1][2] - Changbaishan's shareholder, Jilin Forest, plans to reduce its holdings by no more than 2.7236 million shares [1] Other Corporate Activities - Xi'an Tourism plans to raise no more than 300 million yuan through a private placement to its controlling shareholder [1] - Great Wall Technology has terminated its plans for a change in control and will resume trading on November 10 [1]

Key Points - The article highlights significant announcements from various companies, including investment projects, contract wins, share buybacks, and changes in shareholding [1][2] Company Announcements - Chunzhong Technology clarified that its business does not involve the production of liquid-cooled servers [1] - Founder Technology's subsidiary plans to invest 1.364 billion yuan in the expansion of an artificial intelligence production base in Chongqing [1] - Chongqing Construction Group won a contract for an engineering project valued at approximately 1.839 billion yuan [1] - Guocheng Mining intends to acquire 60% of Guocheng Industry for 3.168 billion yuan [1] - Ruikang Pharmaceutical completed a share buyback, repurchasing 2.31% of its shares [1] Sales Data - Jianghuai Automobile reported October sales of 31,500 units, a year-on-year increase of 5.49% [1] - GAC Group's October automobile sales were 170,700 units, reflecting a year-on-year decline of 8.10% [1] Shareholding Changes - Jiangsu Cable's controlling shareholder plans to increase its stake by 100 million to 150 million yuan [2] - Ginseng Mountain's shareholder, Jilin Forest Industry, intends to reduce its holdings by up to 2.7236 million shares [2] Other Developments - Xi'an Tourism plans to raise no more than 300 million yuan through a private placement to its controlling shareholder [2] - Great Wall Technology has terminated plans for a change in control and will resume trading on November 10 [2]

Group 1 - The core point of the article is that Ruikang Pharmaceutical (002589) announced a share buyback, having repurchased a total of 34,638,659 shares, which represents 2.31% of the company's total share capital [1]

Core Viewpoint - 瑞康医药 has completed its share repurchase plan, acquiring a total of 34,638,659 shares, which represents 2.31% of the company's total share capital [1] Summary by Categories Share Repurchase Details - The company repurchased shares through a centralized bidding transaction method, with a total payment amounting to RMB 101,475,367.91 (excluding transaction fees) [1] - The highest transaction price was 3.08 RMB per share, while the lowest was 2.75 RMB per share [1] - The repurchase period spanned from February 14, 2025, to November 6, 2025 [1] Compliance and Implementation - The total amount spent on the repurchase has reached the lower limit of the planned repurchase funds and has not exceeded the upper limit [1] - The repurchase prices did not exceed the upper limit set in the repurchase plan [1] - The repurchase complies with relevant laws and regulations and aligns with the established share repurchase plan [1]

证券代码：002589 证券简称：瑞康医药 公告编号：2025-053 瑞康医药集团股份有限公司 关于回购结果暨股份变动的公告 瑞康医药集团股份有限公司（以下简称"公司"）于 2024 年 11 月 7 日召开 第五届董事会第十次会议，审议通过了《关于回购公司股份方案的议案》。该议 案同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回购公司部 分已发行的人民币普通股（A 股），用于股权激励或实施员工持股计划。本次回 购资金总额不低于人民币 10,000 万元（含）且不超过人民币 20,000 万元（含）， 回购价格不超过人民币 4.50 元/股。具体回购股份的数量以回购期满时实际回购 的股份数量为准。回购期限自董事会审议通过本次回购股份方案之日起不超过十 二个月。具体内容详见公司于 2024 年 11 月 11 日、2024 年 12 月 12 日等在巨潮 资讯网上披露的相关公告。 截至本公告日，公司本次回购股份实施期限已经届满，公司已按披露的回购 方案完成回购。根据《上市公司股份回购规则（2025 年修订）》和《深圳证券 交易所上市公司自律监管指引第 9 号—回购股份（2025 年修订）》等相关法律 ...

Core Viewpoint - Ruikang Pharmaceutical has completed its share repurchase plan as of November 6, with a total of 34,638,659 shares repurchased, accounting for 2.31% of the company's total share capital [1] Summary by Relevant Sections - **Share Repurchase Details** - The repurchase was conducted through centralized bidding transactions [1] - The highest transaction price was 3.08 CNY per share, while the lowest was 2.75 CNY per share [1] - The total amount paid for the repurchase was 101 million CNY [1] - **Purpose of Repurchased Shares** - The repurchased shares will be used for equity incentives or to implement an employee stock ownership plan [1] - If the shares are not utilized for these purposes within 36 months, the unused portion will be legally canceled [1] - **Financial Impact** - The share repurchase is not expected to have a significant impact on the company's financials [1] - During the implementation period, relevant parties did not engage in buying or selling the company's stock [1]

Core Viewpoint - Ruikang Pharmaceutical (002589) announced the repurchase of 30,504,859 shares, representing 2.03% of the company's total share capital, through a centralized bidding trading method as of November 4, 2025 [1] Summary by Category - **Company Actions** - The company has initiated a share repurchase program, accumulating a total of 30,504,859 shares [1] - The repurchased shares account for 2.03% of the current total share capital of the company [1]

格隆汇11月5日丨瑞康医药(002589.SZ)公布，截至2025年11月4日，公司通过回购专用证券账户以集中 竞价交易方式累计回购公司股份3050.49万股，占公司目前总股本的2.03%，最高成交价为3.08元/股，最 低成交价为2.75元/股，成交金额为8929.61万元（不含交易费用）。 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-052 1 瑞康医药集团股份有限公司 关于回购公司股份比例达到 2 %暨回购进展的公告 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 11 月 7 日召开第五届董事会第十次会议，审议通过了《关于回购公司股份方 案的议案》，同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回 购公司部分已发行的人民币普通股（A 股），本次回购股份将用于实施员工持 股计划，回购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的价格不超过人民币 4.5 元/股（含），具体回购 股份的数量以回购期限届满或回购完毕时实际回购的股份数量为准，实施期限为 董事会审议通过回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 11 月 11 日在巨潮资讯网披露《第五届董事会第十次会议决议的公告》（2024-036） 及《关于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的公告》（公 告编号：2024-037）、2024 年 12 月 12 日在巨潮资讯网披露《回购报告书》 ...

Core Viewpoint - The company announced a share buyback plan, intending to repurchase 27,826,259 shares, which represents 1.85% of its total share capital, with a total transaction amount of 81.4746 million yuan [1] Summary by Categories - **Share Buyback Details** - The company will repurchase shares through a dedicated securities account via centralized bidding [1] - The maximum transaction price is set at 3.08 yuan per share, while the minimum price is 2.75 yuan per share [1] - The total amount for the share buyback is 81.4746 million yuan, excluding transaction fees [1] - **Compliance and Regulations** - The share buyback aligns with the company's established repurchase plan and complies with relevant laws and regulations [1]